Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
Veradermics, Incorporated most recently reported annual revenue of $0, a net loss of $70.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Veradermics, Incorporated: net profit was positive in 0 of 3 reported years; the most recent year shows a net loss of $70.0M.
Income Statement — 3 Years (USD millions)
Metric
2023
2024
2025
Revenue
$0
$0
$0
Operating Expenses
$17.0M
$27.0M
$72.0M
Operating Profit
−$17.0M
−$27.0M
−$72.0M
Other Income
$1.0M
$0
$2.0M
Interest
$0
$1.0M
$0
Depreciation
$0
$0
$0
Profit Before Tax
−$16.0M
−$26.0M
−$70.0M
Tax rate (%)
0.0%
0.0%
0.0%
Net Profit
−$16.0M
−$26.0M
−$70.0M
EPS
−$0.08
−$37.05
−$111.91
Quarterly Results — Last 8 Quarters (USD millions)
Metric
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
$6.0M
$13.0M
$16.0M
$20.0M
$23.0M
$30.0M
$30.0M
$29.0M
Operating Profit
−$6.0M
−$13.0M
−$16.0M
−$20.0M
−$23.0M
−$30.0M
−$30.0M
−$29.0M
Interest
$0
$0
$0
$0
$1.0M
$0
$0
$0
Profit Before Tax
−$6.0M
−$12.0M
−$16.0M
−$20.0M
−$22.0M
−$27.0M
−$24.0M
−$21.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$6.0M
−$12.0M
−$16.0M
−$20.0M
−$22.0M
−$27.0M
−$24.0M
−$21.0M
EPS
−$0.03
−$0.73
−$0.51
−$0.64
−$0.76
−$0.80
−$0.58
−$0.50
Over the 3 years reported for Veradermics, Incorporated, borrowings decreased from $1.0M in 2023 to $0 in 2025, cash stood at $22.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 16.89 times.
Balance Sheet — 3 Years (USD millions)
Metric
2023
2024
2025
Total Assets
$18.0M
$59.0M
$153.0M
Current Assets
$18.0M
$56.0M
$152.0M
Cash
$16.0M
$53.0M
$22.0M
Inventory
$0
$0
$0
Receivables
$0
$1.0M
$1.0M
Fixed Assets
$0
$0
$0
Capital Work in Progress
$0
$0
$0
Investments
$1.0M
$4.0M
$120.0M
Other Assets
$0
$0
$0
Total Liabilities
$4.0M
$5.0M
$274.0M
Current Liabilities
$3.0M
$5.0M
$9.0M
Borrowings
$1.0M
$0
$0
Other Liabilities
$3.0M
$5.0M
$274.0M
Equity
$0
$0
$0
Reserves
$15.0M
$55.0M
−$121.0M
For Veradermics, Incorporated, operating cash flow was positive in 0 of 3 reported years; free cash flow in the latest year was negative at $72.0M; free cash flow was positive in 0 of 3 years.
What is Veradermics, Incorporated's annual revenue?
Veradermics, Incorporated (MANE) reported annual revenue of $0 in its most recent fiscal year.
What is Veradermics, Incorporated's net profit?
Veradermics, Incorporated (MANE) reported a net loss of $70.0M in its most recent fiscal year.
What is MANE EV/EBITDA?
Veradermics, Incorporated's enterprise value to EBITDA (EV/EBITDA) ratio is -64.68. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Biotechnology stocks